Opinion|Videos|December 10, 2024
Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Rebyota's FDA approval was based on clinical trial data showing significant reduction in CDI recurrence rates compared to placebo.
- The pivotal trial was a randomized, double-blind, placebo-controlled study demonstrating Rebyota's efficacy in recurrent CDI.
The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the key data that led to the FDA approval of Rebyota for recurrent C difficile infection?
- Who are the target patient populations for Rebyota?
Advertisement
Related to this article
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
4
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
5